Loading patent…
OwnerPablo MENÉNDEZ BUJÁN, Diego SÁNCHEZ MARTÍNEZ +5inventors
InventorsPablo MENÉNDEZ BUJÁN, Diego SÁNCHEZ MARTÍNEZ, Néstor TIRADO CABRERA, Narciso FERNÁNDEZ FUENTES, Victor Manuel DÍAZ CORTÉS, Maria José MANSILLA LÓPEZ, Alba GARCÍA PÉREZ
Estimating the term…
The present invention provides therapeutics for the treatment of CCR9-positive cancers such as T-cell acute lymphoblastic leukemia. In particular, the present invention provides a CCR9 targeting moiety. The present invention furthermore relates to a CCR9 targeting moiety comprising a further targeting moiety, preferably a CD1a targeting moiety, a dual CAR comprising a CCR9 and a CD1a targeting moiety, their use in the treatment of CCR9 and/or CD1a positive cancers, and the use of a CCR9 targeting moiety and a separate CD1a targeting moiety for such treatment.
A CCR9 targeting moiety that specifically binds to the amino acid sequence of SEQ ID NO:1 (SMEDYVNFN).
A CCR9 targeting moiety comprising an antibody, F(ab′) 2, Fab, scFab or scFv, said antibody, F(ab′)2, Fab, scFab or scFv comprising
The CCR9 targeting moiety according to any one of the preceding claims, wherein the CCR9 targeting moiety is a scFv comprising
The CCR9 targeting moiety according to any one of the preceding claims, wherein the CCR9 targeting moiety comprises the amino acid sequence of SEQ ID NO:16, SEQ ID NO:
The CCR9 targeting moiety or CAR of any one of the preceding claims further comprising a second targeting-moiety, wherein said second targeting moiety is selected from a CD3, CD4, CD5, CD7, CD37, CD30, CD33, CD99, CCR7, CDR3, TRBC1/2, or CD1a targeting moiety, preferably wherein said second targeting moiety is a CD1a targeting moiety.
The CCR9 targeting moiety or CAR of any one of the preceding claims, wherein the CD1a targeting moiety is a scFv comprising a VL domain consisting of SEQ ID NO:31 or SEQ ID NO:
Dependencies are inferred from the claim text.